WallStSmart

Hinge Health, Inc. (HNGE)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 281% more annual revenue ($2.46B vs $646.34M). RCM leads profitability with a -2.5% profit margin vs -78.9%. RCM earns a higher WallStSmart Score of 39/100 (F).

HNGE

Hold

36

out of 100

Grade: F

Growth: 7.3Profit: 3.5Value: 6.0Quality: 5.0
Piotroski: 3/9Altman Z: -2.71

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 6.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HNGEUndervalued (+23.6%)

Margin of Safety

+23.6%

Fair Value

$50.74

Current Price

$56.02

$5.28 discount

UndervaluedFair: $50.74Overvalued
RCMUndervalued (+47.9%)

Margin of Safety

+47.9%

Fair Value

$27.45

Current Price

$14.31

$13.14 discount

UndervaluedFair: $27.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HNGE2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
47.2%10/10

Revenue surging 47.2% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

HNGE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
39.5x2/10

Trading at 39.5x book value

Return on EquityProfitability
-136.0%2/10

ROE of -136.0% — below average capital efficiency

EPS GrowthGrowth
-94.4%2/10

Earnings declined 94.4%

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : HNGE

The strongest argument for HNGE centers on Revenue Growth, Debt/Equity. Revenue growth of 47.2% demonstrates continued momentum.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : HNGE

The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

HNGE profiles as a hypergrowth stock while RCM is a turnaround play — different risk/reward profiles.

HNGE is growing revenue faster at 47.2% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RCM scores higher overall (39/100 vs 36/100) and 14.7% revenue growth. HNGE offers better value entry with a 23.6% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hinge Health, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.

Visit Website →

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) is a premier provider of technology-driven revenue cycle management services that enhance the financial performance of healthcare organizations nationwide. Utilizing cutting-edge analytics and industry insights, R1 RCM delivers holistic solutions that streamline billing processes and boost operational efficiencies for a wide range of clients, including hospitals and outpatient facilities. The company’s innovative methodologies not only optimize revenue capture but also significantly improve patient experiences, solidifying its position as a pivotal player in the dynamic healthcare landscape. With a strategic focus on expanding its service capabilities and market penetration, R1 RCM is well-positioned to meet the surging demand for sophisticated revenue cycle solutions within the healthcare industry.

Want to dig deeper into these stocks?